These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 32354950

  • 21. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y, Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, Hsiao PC, Chen CC, Wang PN, Shih LY.
    Cancer Sci; 2022 Oct; 113(10):3518-3527. PubMed ID: 35869805
    [Abstract] [Full Text] [Related]

  • 22. H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.
    Jamali NS, Raja Sabudin RZA, Alauddin H, Ithnin A, Tumian NR, Jalil N, Awai R, Abu Amis SH, Shuib S.
    Malays J Pathol; 2021 Apr; 43(1):63-68. PubMed ID: 33903307
    [Abstract] [Full Text] [Related]

  • 23. The e1a3 BCR-ABL1 fusion transcript in Philadelphia chromosome-positive acute lymphoblastic leukaemia: a case report.
    Chen Z.
    Hematology; 2023 Dec; 28(1):2186040. PubMed ID: 36912524
    [Abstract] [Full Text] [Related]

  • 24. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
    Burmeister T, Reinhardt R.
    Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
    [Abstract] [Full Text] [Related]

  • 25. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
    Gendron N, Belhouachi N, Morel V, Azgui Z, Maloum K, Nguyen-Khac F, Cayuela JM, Davi F, Merle-Béral H, Chapiro E.
    Ann Biol Clin (Paris); 2014 Apr; 72(3):359-66. PubMed ID: 24876147
    [Abstract] [Full Text] [Related]

  • 26. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P.
    Acta Haematol; 2009 Apr; 122(1):11-6. PubMed ID: 19641300
    [Abstract] [Full Text] [Related]

  • 27. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
    Jabbour E, Kantarjian H.
    Am J Hematol; 2024 Nov; 99(11):2191-2212. PubMed ID: 39093014
    [Abstract] [Full Text] [Related]

  • 28. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 29. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
    Li C, Wang Y, Xu D, Zhang P, Ding X, Zhang N, Xiao M, Huang L, Meng L.
    Clin Lab; 2015 Sep 05; 61(1-2):183-6. PubMed ID: 25807654
    [Abstract] [Full Text] [Related]

  • 30. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X, Pan J, Qiu H, Cen J, Xue Y, Chen S, Shen H, Yao L, Zhang J, Wu Y, Chen Y.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar 05; 35(3):210-4. PubMed ID: 24666486
    [Abstract] [Full Text] [Related]

  • 31. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 05; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 32. Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring.
    Crampe M, Haslam K, Groarke E, Kelleher E, O'Shea D, Conneally E, Langabeer SE.
    Case Rep Hematol; 2017 Aug 05; 2017():9071702. PubMed ID: 29123930
    [Abstract] [Full Text] [Related]

  • 33. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
    Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP.
    BMC Cancer; 2013 Apr 02; 13():173. PubMed ID: 23547655
    [Abstract] [Full Text] [Related]

  • 34. The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.
    Burmeister T, Bullinger L, le Coutre P.
    Acta Haematol; 2023 Apr 02; 146(5):413-418. PubMed ID: 37231781
    [Abstract] [Full Text] [Related]

  • 35. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC, SAKK and the German CML Study Group.
    Haematologica; 2014 Sep 02; 99(9):1441-7. PubMed ID: 24837466
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22).
    Tirrò E, Massimino M, Stella S, Zammit V, Consoli ML, Pennisi MS, Vitale SR, Romano C, Pirosa MC, Martino E, DI Gregorio S, Puma A, DI Raimondo F, Manzella L, Stagno F.
    Anticancer Res; 2019 Jul 02; 39(7):3893-3899. PubMed ID: 31262918
    [Abstract] [Full Text] [Related]

  • 37. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.
    BMC Cancer; 2016 Aug 02; 16():572. PubMed ID: 27485109
    [Abstract] [Full Text] [Related]

  • 38. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K, Asagiri T, Kamioka M, Kojima K.
    Rinsho Ketsueki; 2021 Aug 02; 62(3):180-185. PubMed ID: 33828011
    [Abstract] [Full Text] [Related]

  • 39. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akkaynak DZ, Dag IM, Ilhan O.
    Expert Opin Pharmacother; 2016 Oct 02; 17(14):1851-8. PubMed ID: 27501474
    [Abstract] [Full Text] [Related]

  • 40. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
    May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S, Genomics England Research Consortium, Willis F, Apperley JF, Innes AJ.
    BMC Med Genomics; 2023 Jul 26; 16(1):172. PubMed ID: 37496024
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.